FDA Plays

[barefootrunner]

I do think the tablet formulation will get approved, but this is being overshadowed by the recent Par Pharma generic ZEGERID victory. I think people are still focused on this and are concerned that SNTS' cash cow - ZEGERID - will be vanquished by generic sales. Plus the overall market is not helping things.

I still think SNTS is a solid company and is WAY oversold at these levels. I was previously in, but got stopped out once it fell below $3.00.

Keeping an eye on it for re-entry if/when it finds a bottom.